UnitedHealth Group (UNH)
Salud / Seguros de salud (seguros de salud gestionados)
The largest U.S. health insurer (UnitedHealthcare) + Optum (services, pharmacy, data), emerging from a 2025 earnings trough (the medical care ratio (MCR) jumped to 89%). At ~$398 —already recovered from the panic ($234→$398)— it trades at ~26× depressed earnings and ~15× normalized earnings: Fairly valued, with margin recovery and the regulatory overhang as the variables.
- Price
- $397.78
- Intrinsic value (5y, base)
- $514
- Total annual return (5y)
- 7.7%
- Status (nominal)
- Fairly valued
- Margin of safety
- +13%
The essentials
- The largest U.S. health insurer (UnitedHealthcare) + Optum (services/pharmacy/data, higher margin). FY2025 was a trough: the medical care ratio jumped to 89.1% and operating profit fell 41% to $19bn.
- It is a trough that reverts, not a broken business: in Q1'26 UnitedHealthcare is already recovering (+9% operating, MCR improving) as it reprices. It is valued on normalized earnings (~$30 adjusted EPS), not the depressed figure.
- Already re-rated off the panic ($234→~$398): at ~26× depressed earnings and ~15× normalized earnings → Fairly valued. Dividend 2.2% (17 years, never cut). The tail risk is the DOJ + Medicare Advantage funding.
Intrinsic value — two valuation methods
Total return at 5 years: 7.7%/year = 5.3% appreciation + 2.4% dividend. The target price ($514) is ex-dividend; the $54 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $589 · Multiples $460) exceeds the market price ($398).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $398 trades ~13.4% below its value discounted to today (~$460); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($514) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$291.
Thesis
The business
UnitedHealth is a quality compounder that took a hit: the largest health insurer + Optum (higher-margin services), with a moat of scale, data, and vertical integration intact. But 2025 exposed that the part bearing medical risk is at the mercy of a cost-and-rate cycle, and that the regulatory environment for Medicare Advantage and pharmacy is more uncertain. The quality of the business did not break; the certainty of the margin and the valuation premium did come down.
The valuation
It is valued on P/E over normalized adjusted earnings, not the 2025 depressed figure — last year is a mechanical trough (the medical care ratio jumped to 89%) that normalizes as plans reprice, treated as a trough that reverts (analogous to a cycle). Net income yields the equity directly (it is an insurer: debt backs reserves, EV does not apply).
The base scenario projects a value of ~$514 per share over five years, an annual return of ~+8% from the current ~$398. At today's price it trades at ~26× depressed earnings (the trailing figure misleads) and at ~15× normalized earnings; as earnings recover, the multiple compresses toward ~14×. The stock has already re-rated off the panic low ($234 → ~$398), so the panic bargain has already been captured — the return from here comes from earnings recovery plus the dividend (~2.2%).
The margin of safety
The verdict is Fairly valued: It trades close to intrinsic value, far from the required margin of safety.. At ~$398 the expected return (~+8%) comes from earnings normalization (from the 2025 trough toward ~$30 of adjusted EPS) plus a ~2.2% dividend that was never cut through the crisis. The margin of safety is moderate: the recovery is real and visible (the insurance business is already repricing), but the panic re-rating has already occurred and the regulatory overhang (Medicare Advantage, the DOJ) is a tail risk that warrants the discount.
What to watch
The central disconfirmation: is the Medicare Advantage cost shock a cycle (it normalizes, as the insurance business's Q1'26 suggests, +9% operating) or a structural funding reset (the 2025 margin is the new base)? The signals: the medical care ratio's quarter-by-quarter path, the margin on the 2027-2028 Medicare Advantage rates, and whether Optum Health returns to profitability. And the regulatory overhang: risk-adjustment audits and DOJ activity —no charges so far—, a tail risk over the Medicare Advantage margin engine.
Educational / informational. Does not constitute investment advice.